	Type	L #	Hits	Search Text	DBs	Time Stamp	Comments	Error Definition	Errors
1	BRS	L1	36262	histidine	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/13 14:17			0
2	BRS	L2	1533	1 same stabiliz$3	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/13 14:22			0
3	BRS	L3	182	(glucagon adj like adj peptide adj "2") or glp-2	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/13 15:01			0
4	BRS	L4	1	2 same 3	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/13 14:19			0
5	BRS	L5	1062	2 same (polypeptide or peptide or hormone)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/13 14:21			0
6	BRS	L6	157	5 same (composition or formulation)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/13 14:21			0
7	BRS	L7	126	5 same (composition or formulation) same phosphate	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/13 14:22			0
8	BRS	L8	17	1 near stabiliz$3	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/13 14:42			0
9	BRS	L9	5540	glucagon	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/13 14:42			0
10	BRS	L10	1	2 same 9	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/13 14:42			0
11	BRS	L11	821	glucagon adj like adj peptide	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/13 15:01			0

	Type	L #	Hits	Search Text	DBs	Time Stamp	Comments	Error Definition	Errors
12	BRS	L12	0	2 same 11	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/13 15:02			0
13	BRS	L13	2	6120761.pn.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/13 15:03			0
14	BRS	L14	0	2 same 13	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/13 15:04			0
15	BRS	L15	1	2 and 13	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/13 15:37			0
16	BRS	L19	48231	phosphate adj buffer	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/13 16:20			0
17	BRS	L20	36262	histidine	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/13 16:20			0
18	BRS	L21	121152	(bulking adj agent) or mannitol or sucrose	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/13 16:21			0
19	BRS	L22	2	3 same 19 same 20 same 21	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/13 16:21			0
20	BRS	L23	12	((glucagon adj like adj peptide adj "2") or glp-2) same receptor same antagonist	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/13 16:35			0
21	BRS	L24	1	kit same (((glucagon$1like adj peptide$12) or glp-2) same (phosphate adj buffer) same histidine same ((bulking adj agent) or mannitol or sucrose))	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/13 16:36			0

	Type	L #	Hits	Search Text	DBs	Time Stamp	Comments	Error Definition	Errors
22	BRS	L25	0	((glucagon adj like adj peptide adj "2") or glp-2) same lyopholiz$	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/13 16:36			0
23	BRS	L26	1	isaacs adj indu.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/13 16:36			0

```
FILE 'MEDLINE' ENTERED AT 16:41:18 13 SEP 2003

FILE 'CAPLUS' ENTERED AT 16:41:18 ON 13 SEP 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 16:41:18 ON 13 SEP 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'EMBASE' ENTERED AT 16:41:18 ON 13 SEP 2003
COPYRIGHT (C) 2003 Elsevier Science B.V.  All rights reserved.

FILE 'SCISEARCH' ENTERED AT 16:41:18 ON 13 SEP 2003
COPYRIGHT 2003 THOMSON ISI

FILE 'AGRICOLA' ENTERED AT 16:41:18 ON 13 SEP 2003

=> s (glucagon like peptide 2) or glp-2
L1         1319 (GLUCAGON LIKE PEPTIDE 2) OR GLP-2

=> s phosphate buffer
L2        77082 PHOSPHATE BUFFER

=> s histidine
L3       162033 HISTIDINE

=> s (bulking agent) or mannitol or sucrose
L4       376996 (BULKING AGENT) OR MANNITOL OR SUCROSE

=> s l1 (p) l2 (p) l3 (p) l4
L5             1 L1 (P) L2 (P) L3 (P) L4

=> d l5 1 ibib abs

L5   ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER:         2001:507555  CAPLUS
DOCUMENT NUMBER:          135:97491
TITLE:                    GLP-2 formulations
INVENTOR(S):              Isaacs, Indu J.
PATENT ASSIGNEE(S):       NPS Allelix Corp., Can.
SOURCE:                   PCT Int. Appl., 33 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.          KIND  DATE           APPLICATION NO.   DATE
     ---------------     ----  --------       ---------------   --------
     WO 2001049314       A2    20010712       WO 2000-US35512   20001229
     WO 2001049314       A3    20020103
         W:  AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,
             DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,
             JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,
             MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,
             TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ,
             MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     US 2001027180       A1    20011004       US 2000-750022    20001229
     EP 1246639          A2    20021009       EP 2000-988416    20001229
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
     JP 2003519195       T2    20030617       JP 2001-549681    20001229
PRIORITY APPLN. INFO.:                    GB 1999-30882    A   19991230
                                          WO 2000-US35512  W   20001229
AB   The invention is directed to formulations of  ***GLP***  -  ***2***
     peptides and analogs thereof exhibiting superior stability following
     storage and/or exposure to elevated temps.  The  ***GLP***  -  ***2***
     compns. comprise a  ***GLP***  -  ***2***  peptide or an analog thereof,
     a  ***phosphate***  ***buffer***  , L-  ***histidine***  , and
       ***mannitol***  .
```

```
=> d his

     (FILE 'HOME' ENTERED AT 16:40:56 ON 13 SEP 2003)

     FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT
     16:41:18 ON 13 SEP 2003
L1          1319 S (GLUCAGON LIKE PEPTIDE 2) OR GLP-2
L2         77082 S PHOSPHATE BUFFER
L3        162033 S HISTIDINE
L4        376996 S (BULKING AGENT) OR MANNITOL OR SUCROSE
L5             1 S L1 (P) L2 (P) L3 (P) L4

=> s l3 (a) stabiliz?
L6            36 L3 (A) STABILIZ?

=> s l6 (p) l1
L7             0 L6 (P) L1

=> s l6 (p) (protein or polypeptide or peptide)
L8             4 L6 (P) (PROTEIN OR POLYPEPTIDE OR PEPTIDE)

=> duplicate remove l8
DUPLICATE PREFERENCE IS 'CAPLUS, EMBASE'
KEEP DUPLICATES FROM MORE THAN ONE FILE?  Y/(N):n
PROCESSING COMPLETED FOR L8
L9             4 DUPLICATE REMOVE L8 (0 DUPLICATES REMOVED)

=> d l9 1-4 ibib abs

L9   ANSWER 1 OF 4  CAPLUS  COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER:         1993:142543  CAPLUS
DOCUMENT NUMBER:          118:142543
TITLE:                    Stabilization of microbial lipase with L-histidine
INVENTOR(S):              Naka, Yasuhiro
PATENT ASSIGNEE(S):       Amano Pharmaceutical Co., Ltd., Japan
SOURCE:                   Jpn. Kokai Tokkyo Koho, 9 pp.
                          CODEN: JKXXAF
DOCUMENT TYPE:            Patent
LANGUAGE:                 Japanese
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.        KIND  DATE           APPLICATION NO.   DATE
     ---------------   ----  --------       ---------------   --------
     JP 04370096        A2   19921222       JP 1991-170616    19910614
     JP 3152958         B2   20010403
PRIORITY APPLN. INFO.:                    JP 1991-170616      19910614
AB   Histidine (I) or proteins having N-terminal histidine such as bovine serum
     albumin are used to abolish the inhibition of microbial lipase by bile
     acid salts in duodenum.  A compn. contg. I and microbial lipase is useful
     as a pancreatin substitute for treatment of digestion-assocd. disorders.
     In the presence/absence of I, bile acid salts 4mM inhibited the activity
     of lipase of Rhizopus delemar to degrade olive oil by 7% and 27, resp.

L9   ANSWER 2 OF 4  CAPLUS  COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER:         1991:77233  CAPLUS
DOCUMENT NUMBER:          114:77233
TITLE:                    Studies of synthetic helical peptides using circular
                          dichroism and nuclear magnetic resonance
AUTHOR(S):                Bradley, Erin K.; Thomason, John F.; Cohen, Fred E.;
                          Kosen, Phyllis Anne; Kuntz, Irwin D.
CORPORATE SOURCE:         Dep. Pharm. Chem., Univ. California, San Francisco,
                          CA, 94143, USA
SOURCE:                   Journal of Molecular Biology (1990), 215(4), 607-22
                          CODEN: JMOBAK; ISSN: 0022-2836
DOCUMENT TYPE:            Journal
LANGUAGE:                 English
AB   A set of 17-residue synthetic peptides were designed to be monomeric
     helixes in aq. soln.  CD expts. indicate the presence of helical structure
     in aq. soln. at low temp. and low pH.  The 2-dimensional NMR results for
     one of the peptides show a segment of 10 residues which clearly meets all
     of the criteria for the existence of helical structure at both 5.degree.
     and 15.degree..  The 1st 4 residues of the peptide are in a largely
     extended conformation.  Calcns. suggest that residues 5 through 14 are
     significantly helical at 5.degree..  When the temp. is increased, CD
     spectra indicate that the helical content decreases.  At 15.degree. the
     3JN.alpha. coupling consts. increase in the helical region, indicating an
```

increase in motion or conformational averaging in the helical segment. None of the peptides has pH titration behavior consistent with salt bridge stabilization of helical conformation. These data lend themselves to interpretation with the helix dipole model and specific side-chain interactions. When the N and C termini charges are removed the helical content of the peptides increases. The amt. of helicity increases as the pH is lowered, due to the ionization of His16. Much of the helical stabilization appears to be due to a specific side-chain interaction between His16 and Tyr12.

L9 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1986:502588 CAPLUS
DOCUMENT NUMBER: 105:102588
TITLE: Histidine-stabilized immunoglobulin
INVENTOR(S): Zolton, Raymond P.; Nasser, Jennifer A.
PATENT ASSIGNEE(S): Ortho Diagnostic Systems, Inc., USA
SOURCE: U.S., 8 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4597966	A	19860701	US 1985-689882	19850109
AU 8651892	A1	19860717	AU 1986-51892	19860107
AU 590737	B2	19891116		
CA 1285225	A1	19910625	CA 1986-499148	19860107
EP 187712	A2	19860716	EP 1986-300087	19860108
EP 187712	A3	19880803		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
JP 61218528	A2	19860929	JP 1986-1483	19860109

PRIORITY APPLN. INFO.: US 1985-689882 19850109
AB ***Histidine*** - ***stabilized*** therapeutic Ig prepns. and a method for their manuf. are disclosed. It is particularly well suited for stabilization of human IgG prepns. having a relatively low ***protein*** content. Preferred stabilized human .gamma.-globulin prepns. comprise about 5 wt.% or less .gamma.-globulin, histidine at a concn. of about 0.025-0.2M, and optionally glycine at 0.05-0.5 M. The pH value of the prepns. is at least 6.0 but not more than 7.0. A pH value of about 6.4 is most preferred. Cond. of the prepns. is about 2-4 millisiemens at 5.degree., preferably about 2.5-3.5 millisiemens at 5.degree., and most preferably about 2.7 millisiemens at 5.degree..

L9 ANSWER 4 OF 4 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V. on STN
ACCESSION NUMBER: 75068732 EMBASE
DOCUMENT NUMBER: 1975068732
TITLE: Multiple aggregation states of phosphoribosyladenosine triphosphate synthetase.
AUTHOR: Parsons S.M.; Koshland Jr D.E.
CORPORATE SOURCE: Dept. Biochem., Univ. California, Berkeley, Calif. 94720, United States
SOURCE: Journal of Biological Chemistry, (1974) 249/13 (4119-4126).
CODEN: JBCHA3
DOCUMENT TYPE: Journal
FILE SEGMENT: 004 Microbiology
029 Clinical Biochemistry
LANGUAGE: English
AB The association states of phosphoribosyladenosine triphosphate synthetase from Salmonella typhimurium were studied using ultracentrifugation, gel filtration, and fluorescence spectroscopic techniques. The enzyme exists predominantly as a hexamer at 25 and 37.degree. under mild solvent conditions. At 4-7.5.degree. it aggregates to species smaller and larger than a hexamer depending on ***protein*** concentration. High ionic strength cesium chloride at 25.degree. leads to a species larger than the hexamer. Lower ionic strength, pH 10, or aging dissociate the enzyme to a dimer. The combination of low ionic strength and pH 10 can dissociate the enzyme further to a monomer. Either of the substrates or ***histidine*** ***stabilizes*** the hexamer form of the enzyme, but sodium ion is necessary for effective stabilization by histidine. Active enzyme was shown to be a hexamer under assay conditions, even when incubated under conditions leading to indefinite aggregation prior to ultracentrifugation in assay media.

=> d his

```
     (FILE 'HOME' ENTERED AT 16:40:[redacted] ON 13 SEP 2003)

     FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT
     16:41:18 ON 13 SEP 2003
L1          1319 S (GLUCAGON LIKE PEPTIDE 2) OR GLP-2
L2         77082 S PHOSPHATE BUFFER
L3        162033 S HISTIDINE
L4        376996 S (BULKING AGENT) OR MANNITOL OR SUCROSE
L5             1 S L1 (P) L2 (P) L3 (P) L4
L6            36 S L3 (A) STABILIZ?
L7             0 S L6 (P) L1
L8             4 S L6 (P) (PROTEIN OR POLYPEPTIDE OR PEPTIDE)
L9             4 DUPLICATE REMOVE L8 (0 DUPLICATES REMOVED)

=> s l1 (p) lyophiliz?
L10            0 L1 (P) LYOPHILIZ?

=> s disease (p) l1
L11          132 DISEASE (P) L1

=> s L11 (p) L2 (p) l3 (p) l4
L12            0 L11 (P) L2 (P) L3 (P) L4

=> s isaacs indu/au
L13            4 ISAACS INDU/AU

=> s l13 and l1
L14            0 L13 AND L1

=> d his

     (FILE 'HOME' ENTERED AT 16:40:56 ON 13 SEP 2003)

     FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT
     16:41:18 ON 13 SEP 2003
L1          1319 S (GLUCAGON LIKE PEPTIDE 2) OR GLP-2
L2         77082 S PHOSPHATE BUFFER
L3        162033 S HISTIDINE
L4        376996 S (BULKING AGENT) OR MANNITOL OR SUCROSE
L5             1 S L1 (P) L2 (P) L3 (P) L4
L6            36 S L3 (A) STABILIZ?
L7             0 S L6 (P) L1
L8             4 S L6 (P) (PROTEIN OR POLYPEPTIDE OR PEPTIDE)
L9             4 DUPLICATE REMOVE L8 (0 DUPLICATES REMOVED)
L10            0 S L1 (P) LYOPHILIZ?
L11          132 S DISEASE (P) L1
L12            0 S L11 (P) L2 (P) L3 (P) L4
L13            4 S ISAACS INDU/AU
L14            0 S L13 AND L1

=> log y
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                  ENTRY    SESSION
FULL ESTIMATED COST                               56.34      56.55

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)      SINCE FILE      TOTAL
                                                  ENTRY    SESSION
CA SUBSCRIBER PRICE                               -2.60      -2.60

STN INTERNATIONAL LOGOFF AT 16:47:59 ON 13 SEP 2003
```